Table 1.

Cyclin E expression in different types of cancer

Type of carcinoma	Total number of cases	Number of cases of cyclin E overexpression	Rate of cyclin E overexpression	Significance and conclusion of the study	Reference
Gastric cancer	84	34	40.5%	Cyclin E overexpression was related to poor survival rates; it may useful as a prognostic measure in gastric cancer.	[23]
Knockout of INMAP	89	35	39.3%	Cyclin E overexpression was an important prognostic factor with regard to survival. Patients with low cyclin E expression had higher five-year survival rates than patients with high expression.	[24]
Hepatocellular cancer and intraoperative cancer	90	45	50%	Cyclin E overexpression was associated with the formation of tumor thrombi, tumor invasion and metastatic potential.	[25]
Pancreatic ductal adenocarcinoma	118	39	33.1%	Cyclin E overexpression was identified as an independent predictor of poor outcomes in pancreatic cancer patients.	[26]
Metastatic colon cancer	114	32	28%	Cyclin E overexpression in cancer was related to an increased risk of tumor recurrence and poor outcomes.	[27]
Rectal cancer	360	104	29%	Evaluation of cyclin E expression may provide useful prognostic information for rectal cancer patients.	[28]
Non-small cell lung cancer	156	64	41%	Cyclin E expression was highly variable and determined to play a role in tumor grade and differentiation in NSCLC.	[31]